临床医学工程2024，Vol.31Issue(6)：693-694,2.DOI:10.3969/j.issn.1674-4659.2024.06.0693
达雷妥尤单抗联合IRd方案对复发难治性多发性骨髓瘤患者的治疗效果
Therapeutic Effect of Daleituzumab Combined with IRd Regimen on Patients with Relapsed and Refractory Multiple Myeloma
肖晶晶 1毛沛沛 1乔莎1
作者信息
- 1. 南阳市中心医院血液内科,河南南阳 473000
- 折叠
摘要
Abstract
Objective To explore the effect of daleituzumab combined with IRd regimen in the treatment of patients with relapsed and refractory multiple myeloma(RRMM).Methods A total of 66 patients with RRMM admitted to our hospital from June 2019 to June 2022 were selected and randomly divided into two groups.The reference group was treated with IRd regimen(ixazomib+dexamethasone+lenalidomide),and the study group was treated with dasatuzumab on the basis of the reference group.The clinical efficacy,adverse reactions and recurrence rate were compared between the two groups.Results After 8 courses of treatment,the total remission rate of the study group was 93.94％,significantly higher than 57.58％of the reference group(P＜0.05).During the treatment period,no significant difference was found in the total incidence of adverse reactions between the study group(63.64％)and the reference group(45.45％),P＞0.05.During the 3-month follow-up period after treatment,the recurrence rate of the study group was 6.45％,significantly lower than 52.63％of the reference group(P＜0.05).Conclusions Daleituzumab combined with IRd regimen in the treatment of patients with RRMM has significant effect,which helps to reduce the recurrence rate and does not obviously increase the occurrence of adverse reactions.关键词
达雷妥尤单抗/IRd方案/复发难治性多发性骨髓瘤/治疗效果/不良反应Key words
Daleituzumab/IRd regimen/Relapsed and refractory multiple myeloma/Therapeutic effect/Adverse reaction分类
医药卫生引用本文复制引用
肖晶晶,毛沛沛,乔莎..达雷妥尤单抗联合IRd方案对复发难治性多发性骨髓瘤患者的治疗效果[J].临床医学工程,2024,31(6):693-694,2.
